Key Takeaway
If you're exploring GLP-1 medications for weight loss, you've probably come across two big names: semaglutide vs liraglutide. Both belong to the same drug class. Both mimic a natural hormone that controls appetite and blood sugar.
If you're exploring GLP-1 medications for weight loss, you've probably come across two big names: semaglutide vs liraglutide. Both belong to the same drug class. Both mimic a natural hormone that controls appetite and blood sugar. But they work differently in practice (and the results can vary quite a bit.
Key Takeaways: - Learn how semaglutide and liraglutide work differently - Weight Loss Results: What the Research Shows - Side Effects and Tolerability - Cost and Access: What You'll Actually Pay
Choosing between them matters. The right fit depends on your goals, your schedule, your budget, and how your body responds. This guide breaks down the key differences so you can have a smarter conversation with your provider.
How Semaglutide and Liraglutide Work Differently
| Feature | Semaglutide (Wegovy) | Liraglutide (Saxenda) |
|---|---|---|
| Mechanism | GLP-1 agonist | GLP-1 agonist |
| Weight loss (trials) | ~14.9% (STEP 1 (Wilding et al., NEJM, 2021)) | ~8.0% (SCALE) |
| Dosing frequency | Once weekly | Once daily |
| Half-life | ~7 days | ~13 hours |
| Injections per month | 4 | 30 |
| Top dose | 2.4 mg | 3.0 mg |
| CV outcomes trial | SELECT (positive) | LEADER (positive) |
"The key to successful GLP-1 therapy is setting realistic expectations and supporting patients through the titration phase. The side effects are manageable for most people, but they need to know what to expect.") Dr. Caroline Apovian, MD, Harvard Medical School
Both semaglutide and liraglutide are GLP-1 receptor agonists. They bind to the same receptors in your brain and gut. They slow gastric emptying, reduce appetite, and help regulate blood sugar. So far, so similar.
The biggest difference is how long they stay active in your body. Liraglutide has a half-life of about 13 hours. That means you need to inject it once per day. Semaglutide has a half-life of roughly 7 days. That means one injection per week.
This isn't just a convenience factor. The longer half-life of semaglutide means more consistent drug levels in your system. Some studies suggest this leads to more stable appetite suppression throughout the week. With liraglutide, some people notice their hunger returning before their next dose.
Semaglutide also has a slightly different molecular structure. It's been modified to bind more tightly to albumin in your blood. This is what gives it that extended duration. Both medications were originally developed for type 2 diabetes and later approved at higher doses for weight management.
If you're curious whether a GLP-1 medication might be right for you, to find out.
Weight Loss Results: What the Research Shows
Clinical trials give us a clear picture of how these two medications compare for weight loss.
In the STEP trials, participants on semaglutide 2.4 mg weekly lost an average of about 15% of their body weight over 68 weeks. That's significant. For a 220-pound person, that's roughly 33 pounds.
Liraglutide 3.0 mg daily showed average weight loss of about 8% of body weight in the SCALE trial (Pi-Sunyer et al., NEJM, 2015)s over 56 weeks. Using the same example, that's about 17.5 pounds.
Free Download: Decision Matrix Not sure which GLP-1 medication fits your situation? Our comparison decision matrix lays out dosing, cost, results, and side effects side by side. Get yours free (we'll email it to you instantly. [Download Now]
The difference is meaningful. Semaglutide consistently outperforms liraglutide in head-to-head comparisons. The SUSTAIN 10 (Capehorn et al., Diabetes Metab, 2020) trial directly compared them in type 2 diabetes patients and found semaglutide produced greater reductions in both weight and A1C.
That said, individual results vary widely. Some people respond better to liraglutide. Others can't tolerate semaglutide's side effects but do fine on liraglutide. Your provider can help you figure out which is the better starting point based on your health history.
For a deeper look at semaglutide specifically, check out our .
LEADER vs SELECT: Cardiovascular Outcomes Head-to-Head
Both semaglutide and liraglutide have dedicated cardiovascular outcomes trials) and both showed meaningful heart health benefits. But the trials studied different populations and produced different magnitudes of effect. Understanding these differences matters if you have cardiovascular risk factors.
Check your GLP-1 eligibility
Use our free BMI Calculator to see if you may qualify for physician-supervised GLP-1 therapy.
Try the BMI Calculator →The LEADER trial (Marso et al., NEJM, 2016): LEADER enrolled 9,340 patients with type 2 diabetes and high cardiovascular risk. Participants received liraglutide 1.8 mg daily (the diabetes dose, lower than the 3.0 mg weight loss dose) or placebo for a median of 3.8 years. The primary outcome (a composite of cardiovascular death, nonfatal heart attack, and nonfatal stroke) was reduced by 13% in the liraglutide group (hazard ratio 0.87, 95% CI 0.78-0.97). Cardiovascular death specifically was reduced by 22%. This was the first trial to demonstrate cardiovascular benefits of a GLP-1 medication.
The SELECT trial (Lincoff et al., NEJM, 2023): SELECT enrolled 17,604 adults aged 45 or older with overweight or obesity and established cardiovascular disease, but critically, without diabetes. Participants received semaglutide 2.4 mg weekly (the weight management dose) or placebo for a median of 39.8 months. The primary MACE outcome was reduced by 20% (hazard ratio 0.80, 95% CI 0.72-0.90). This was a larger risk reduction than LEADER, and in a population without diabetes (demonstrating that the cardiovascular benefits are not solely driven by blood sugar improvements.
Key differences between the trials:
| Factor | LEADER (Liraglutide) | SELECT (Semaglutide) |
|---|---|---|
| Population | Type 2 diabetes + CV risk | Obesity + established CVD, no diabetes |
| Sample size | 9,340 | 17,604 |
| Duration | 3.8 years median | 3.3 years median |
| MACE reduction | 13% | 20% |
| CV death reduction | 22% | 15% (non-significant) |
| Drug dose | 1.8 mg daily (diabetes dose) | 2.4 mg weekly (weight dose) |
Both trials are positive, but they tell different stories. LEADER showed that GLP-1 therapy can protect hearts in diabetes patients. SELECT showed that weight management with semaglutide can protect hearts even without diabetes. If you have established cardiovascular disease or multiple risk factors, these findings may influence which GLP-1 your provider recommends.
Oral Semaglutide: A Third Option to Consider
While the injectable forms get most of the attention, oral semaglutide offers an alternative for patients who prefer to avoid injections entirely. Sold under the brand name Rybelsus for type 2 diabetes, oral semaglutide is taken as a daily tablet rather than a weekly injection.
How oral semaglutide works differently: The oral formulation uses a special absorption enhancer called SNAC (sodium N-[8-(2-hydroxybenzoyl) amino] caprylate) that protects the semaglutide molecule from stomach acid and helps it cross the stomach lining into the bloodstream. You must take it on an empty stomach with no more than 4 ounces of plain water, then wait at least 30 minutes before eating, drinking, or taking other medications.
Efficacy compared to injectable forms: Oral semaglutide is currently available at doses up to 14 mg daily for diabetes. At this dose, weight loss is meaningful but lower than injectable semaglutide 2.4 mg) typically around 8-10% of body weight in clinical studies. Higher oral doses (25 mg and 50 mg) are being studied specifically for weight management in the OASIS trial program, with early results showing weight loss approaching that of the injectable form.
When oral semaglutide might make sense: - You have a strong aversion to needles or injections - You are currently on liraglutide and want to move away from daily injections but are not ready for injectable semaglutide - Your provider recommends starting with a lower-potency GLP-1 before advancing to higher doses - You prefer the simplicity of a pill (with the caveat of the strict empty-stomach requirement)
Limitations: The strict dosing requirements (empty stomach, small sip of water, 30-minute wait) can be inconvenient. Bioavailability is lower and more variable than injectable semaglutide, which means blood levels may fluctuate more. And as of 2026, the higher weight management doses are not yet widely available in all markets.
Talk to your provider about whether oral semaglutide could be a stepping stone or alternative in your treatment plan.
Side Effects and Tolerability
Both medications share a similar side effect profile because they work on the same receptors. The most common issues are gastrointestinal: nausea, vomiting, diarrhea, and constipation.
Nausea is the number one complaint with both drugs. Clinical data suggests nausea rates are slightly higher with semaglutide (around 44% in trials) compared to liraglutide (around 39%). However, semaglutide nausea tends to decrease after the first few weeks of dose titration.
With liraglutide, the daily dosing means side effects can feel more constant but milder. With semaglutide, some people report stronger side effects in the first day or two after their weekly injection, followed by relief as the week goes on.
Both medications carry warnings about potential thyroid tumors (based on animal studies), pancreatitis, and gallbladder issues. These serious side effects are rare but worth discussing with your provider.
One advantage of liraglutide's daily dosing: if you experience a bad reaction, the drug clears your system faster. With semaglutide's week-long half-life, a difficult side effect takes longer to resolve.
Discontinuation rates tell an important story. In the STEP 1 trial, approximately 7% of semaglutide participants discontinued due to adverse events. In the SCALE trial, the discontinuation rate for liraglutide was approximately 10%. While these numbers are relatively close, the difference may partly reflect the daily injection burden of liraglutide (patients who experience even mild daily nausea may be more likely to stop a medication that requires daily self-injection than one requiring only weekly dosing. Adherence and persistence are critical factors in long-term outcomes with any weight management medication.
Learn more about managing GI symptoms in our .
Cost and Access: What You'll Actually Pay
Cost is often the deciding factor. Brand-name versions of both medications can be expensive without insurance. The list prices for the weight-loss-specific versions run over $1,000 per month.
Insurance coverage varies widely. Some plans cover one but not the other. Some cover neither for weight loss but will cover them for type 2 diabetes. It's worth checking with your specific plan.
Compounded versions offer another path. Personalized compounded semaglutide prepared by a licensed US-based 503A pharmacy can cost significantly less than brand-name options. This has made semaglutide much more accessible for people paying out of pocket. You can for transparent cost breakdowns.
Liraglutide also has a generic version available in some markets for diabetes, though not specifically for weight loss. The availability and pricing environment changes frequently.
When comparing total cost, remember that liraglutide requires 30 injections per month versus 4 for semaglutide. That means more supplies, more injection site rotation, and more time spent on your routine.
Pediatric and Adolescent Data: What Parents Need to Know
Childhood and adolescent obesity is a growing concern, and GLP-1 medications are increasingly being studied in younger populations. Here is where the evidence stands for each medication.
Liraglutide (Saxenda) in adolescents: Liraglutide 3.0 mg is FDA-approved for weight management in adolescents aged 12 and older with obesity (BMI at or above the 95th percentile for age and sex). The approval was based on a randomized trial of 251 adolescents aged 12-17 that showed a reduction in BMI of approximately 2.65% with liraglutide compared to an increase of 1.14% with placebo over 56 weeks. This makes liraglutide the GLP-1 medication with the most established pediatric track record for weight management.
Semaglutide in adolescents: The STEP TEENS trial studied semaglutide 2.4 mg weekly in 201 adolescents aged 12-17 with obesity. After 68 weeks, participants on semaglutide achieved a mean reduction in BMI of 16.1% compared to a 0.6% increase with placebo. These results are substantially larger than what liraglutide showed in adolescents, mirroring the adult data showing semaglutide's greater potency. The FDA approved Wegovy for adolescents aged 12 and older in late 2022.
Tirzepatide in adolescents: Pediatric trials for tirzepatide are underway but have not yet reported results as of early 2026. The SURMOUNT-PEDS trial is actively enrolling adolescents and is expected to provide data in the coming years.
Important considerations for families: Pediatric obesity treatment is a specialized area. Any GLP-1 medication for a minor should be prescribed by a provider experienced in adolescent medicine, ideally within a full program that includes dietary counseling, physical activity guidance, and behavioral support. GLP-1 medications are not a standalone solution for pediatric obesity (they are one tool within a broader treatment approach.
FormBlends currently serves adults 18 and older. If you are exploring options for an adolescent, we recommend consulting with a pediatric endocrinologist or an obesity medicine specialist at an academic medical center.
Practical Conversion Guidance: Switching from Liraglutide to Semaglutide
If you are currently on liraglutide and considering a switch to semaglutide, here is what the transition typically looks like in clinical practice.
Why patients switch: The most common reasons are convenience (weekly vs daily injections), efficacy (seeking greater weight loss), and cost (compounded semaglutide may be less expensive than brand-name liraglutide in some cases). Some patients also switch because they have maximized their response to liraglutide and want to try a more potent option.
The transition protocol: There is no universally standardized conversion protocol, but most providers follow a similar approach:
- Stop liraglutide. Take your last daily injection as scheduled.
- Start semaglutide the following day or within a few days. There is no required washout period since both medications target the same receptor.
- Begin at the lowest semaglutide dose (0.25 mg weekly). Even though you have been on a GLP-1 medication, your body needs to adjust to semaglutide's longer half-life and different pharmacokinetic profile. Starting low reduces the risk of severe GI side effects during the transition.
- Titrate on the standard schedule. Increase every 4 weeks as tolerated: 0.25 mg, 0.5 mg, 1.0 mg, 1.7 mg, and finally 2.4 mg.
What to expect during the transition: Most patients who switch from liraglutide to semaglutide report a relatively smooth transition because their body is already accustomed to GLP-1 receptor activation. However, side effects can still occur at new dose levels. The first week may feel slightly different because you are no longer injecting daily) some patients notice a mild return of appetite on days 5-7 as they adjust to the weekly dosing pattern.
Dose equivalence note: There is no direct dose equivalence between liraglutide and semaglutide. Liraglutide 3.0 mg daily is not equivalent to any specific semaglutide dose. The two medications have different potencies, receptor binding affinities, and pharmacokinetic profiles. Your provider will titrate semaglutide based on your individual response rather than trying to match your liraglutide dose.
Patient Perspective: "I was on Saxenda for 8 months and lost about 25 pounds, but then I hit a wall. My provider switched me to semaglutide and we started from scratch with the low dose. Within 3 months I was losing again. The weekly injection is so much easier than daily.", Christine M., 38, FormBlends patient (name changed for privacy)
Frequently Asked Questions
Can I switch from liraglutide to semaglutide?
Yes, many people switch from liraglutide to semaglutide. Your provider will typically start you at the lowest semaglutide dose even if you were on a high liraglutide dose. There's usually no waiting period needed between stopping one and starting the other.
Which GLP-1 medication has fewer side effects?
Both have similar side effect profiles. Liraglutide may cause milder but more frequent daily nausea. Semaglutide may cause stronger but less frequent weekly nausea. Most side effects improve within 4-8 weeks on either medication. Your provider can help manage symptoms during the adjustment period.
Is semaglutide always better than liraglutide for weight loss?
Not always. While clinical trials show semaglutide produces greater average weight loss, individual results vary. Some people respond better to liraglutide or tolerate it more easily. The best medication is the one you can stick with consistently. Discuss your options with a licensed provider.
Do I need a prescription for both medications?
Yes. Both semaglutide and liraglutide require a prescription from a licensed healthcare provider. FormBlends connects you with licensed providers who can evaluate whether a GLP-1 medication is appropriate for your situation.
Let's Make This Happen
The research is clear. The options are available. The only question is whether it's right for you. A FormBlends provider can help you decide (no pressure, no commitment.
Sources & References
- Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021;384(11):989-1002. Doi:10.1056/NEJMoa2032183
- Davies M, Færch L, Jeppesen OK, et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2 (Davies et al., Lancet, 2021)). Lancet. 2021;397(10278):971-984. Doi:10.1016/S0140-6736(21)00213-0
- Wadden TA, Bailey TS, Billings LK, et al. Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity (STEP 3 (Wadden et al., JAMA, 2021)). JAMA. 2021;325(14):1403-1413. Doi:10.1001/jama.2021.1831
- Garvey WT, Batterham RL, Bhatt DL, et al. Two-Year Effects of Semaglutide in Adults with Overweight or Obesity (STEP 5 (Garvey et al., Nat Med, 2022)). Nat Med. 2022;28:2083-2091. Doi:10.1038/s41591-022-02026-4
- Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. N Engl J Med. 2023;389(24):2221-2232. Doi:10.1056/NEJMoa2307563
- Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med. 2022;387(3):205-216. Doi:10.1056/NEJMoa2206038
- Garvey WT, Frias JP, Jastreboff AM, et al. Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2 (Garvey et al., Lancet, 2023)). Lancet. 2023;402(10402):613-626. Doi:10.1016/S0140-6736(23)01200-X
- Wadden TA, Chao AM, Engel S, et al. Tirzepatide after intensive lifestyle intervention in adults with overweight or obesity (SURMOUNT-3 (Wadden et al., Nat Med, 2023)). Nat Med. 2023. Doi:10.1038/s41591-023-02597-w
- Aronne LJ, Sattar N, Horn DB, et al. Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity (SURMOUNT-4 (Aronne et al., JAMA, 2024)). JAMA. 2024;331(1):38-48. Doi:10.1001/jama.2023.24945
- Malhotra A, Grunstein RR, Fietze I, et al. Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity. N Engl J Med. 2024;391:1193-1205. Doi:10.1056/NEJMoa2404881
- Pi-Sunyer X, Astrup A, Fujioka K, et al. A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management. N Engl J Med. 2015;373(1):11-22. Doi:10.1056/NEJMoa1411892
- Marso SP, Daniels GH, Tanaka K, et al. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2016;375(4):311-322. Doi:10.1056/NEJMoa1603827
This article is for educational purposes only and does not constitute medical advice. Always consult with a licensed healthcare provider before starting, changing, or stopping any medication or supplement. FormBlends connects you with licensed providers who can evaluate your individual health needs.
Last updated: 2026-03-24